Exelixis

FDA Accepts Exelixis' NDA for Colorectal Cancer Combo, Boosting Valuation Focus

伊克力西斯

Exelixis's 15min chart triggers Bollinger Bands Narrowing and KDJ Death Cross.

Exelixis: Barclays Keeps Equal-Weight Rating, Raises PT to $44 from $41.

Exelixis's 15min chart shows MACD Death Cross, Bollinger Bands Narrowing.

Exelixis:HC Wainwright Raises Buy Rating, PT to $52 from $52

Catalyst<ul> <li>Most analysts rate EXEL Buy or Strong Buy, showing broad institutional optimism.</li> <li>The company maintains strong cash reserves relative to market value.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant(3 bearish vs 1 bullish).</li> <li>Fund flow trends are negative, with medium, large, and extra-large orders showing outflows.</li></ul>

Key Factors

Exelixis increased its 2025 full-year net product revenue guidance by $100 million due to accelerated demand for cabozantinib. FDA accepted Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer, based on Phase 3 trial results. Barclays raised its price target for Exelixis to $44 from $41, maintaining an equal-weight rating.

EXEL News